To Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults
Primary Purpose
Bacterial Infections
Status
Completed
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
GC1107
Tetanus and Diphtheria(Td vaccine)
Sponsored by
About this trial
This is an interventional prevention trial for Bacterial Infections
Eligibility Criteria
Inclusion Criteria:
- healthy Korean adults (age: over 18 years)
- who got the basic vaccination of DTP(Diphtheria, tetanus, pertussis) in the past
- Subjects willing to provide written informed consent and able to comply with the requirements for the study
Exclusion Criteria:
- subjects who have already got the additional vaccination of Td within 5 years
subjects with antitoxin of diphtheria and tetanus ≥1.0 IU/mL (ELISA)
- only applicable in step I
- subjects who have not recovered from the acute disease within 2 weeks
- subjects who have the medical history of allergic disease related to the components of investigational drug
- who got the treatment of blood product and immunoglobulin product within 3 months
- females who are pregnant
- females who are breastfeeding
- subjects who are infected from the diphtheria and tetanus
- subjects who have experienced the severe adverse events for the diphtheria and tetanus vaccination
- Subjects who are scheduled to participate in other clinical trial studies during the study
- Subjects who have participated in any other clinical trials within 4 weeks of the administration of the study
- Those who take the other medicine that affects this study or are vaccinated other vaccines
- Subject who have received adrenocortical hormones or immunosuppressive drug within 4weeks of enrollment
- Subjects with a history of chronic disease obstacles to the study.
- Subjects who have episode of acute febrile (at least 37.4) after injection of vaccine during the study
- Subject who have plan of operation during the study.
- Individuals with other clinically significant medical or psychological condition who are considered by the investigator to be ineligible for the study.
Sites / Locations
- Incheon St. Mary's Hospital Catholic Univ.
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
GC1107
Tetanus and Diphtheria(Td vaccine)
Arm Description
0.5ml, intramuscular, a single dosing
0.5ml, intramuscular, a single dosing
Outcomes
Primary Outcome Measures
seroprotection rate of diphtheria and tetanus
Secondary Outcome Measures
GMT (Geometric Mean Titer)
Boosting response of diphtheria and tetanus compared participants with before and after the injection
Boosting response is defined as more 4 times increase of the antibody titer after the injection
solicited adverse events
unsolicited adverse events
Seroprotection rate according to the respective age group
GMT according to the respective age group
Full Information
NCT ID
NCT02361866
First Posted
April 22, 2014
Last Updated
February 11, 2015
Sponsor
Green Cross Corporation
1. Study Identification
Unique Protocol Identification Number
NCT02361866
Brief Title
To Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults
Official Title
Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults
Study Type
Interventional
2. Study Status
Record Verification Date
February 2015
Overall Recruitment Status
Completed
Study Start Date
May 2014 (undefined)
Primary Completion Date
September 2014 (Actual)
Study Completion Date
October 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Green Cross Corporation
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the effectiveness(immunogeneicity) and safety of 'GC1107' administered intramuscularly in healthy Adults.
Detailed Description
Randomized, double blind, multicenter, phaseⅢ study
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bacterial Infections
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
376 (Actual)
8. Arms, Groups, and Interventions
Arm Title
GC1107
Arm Type
Experimental
Arm Description
0.5ml, intramuscular, a single dosing
Arm Title
Tetanus and Diphtheria(Td vaccine)
Arm Type
Active Comparator
Arm Description
0.5ml, intramuscular, a single dosing
Intervention Type
Biological
Intervention Name(s)
GC1107
Intervention Description
0.5 ml, Intramuscular, single dose(day0)
Intervention Type
Biological
Intervention Name(s)
Tetanus and Diphtheria(Td vaccine)
Intervention Description
0.5ml, Intramuscular, single dose(day0) only applicable step1
Primary Outcome Measure Information:
Title
seroprotection rate of diphtheria and tetanus
Time Frame
28days
Secondary Outcome Measure Information:
Title
GMT (Geometric Mean Titer)
Time Frame
28days
Title
Boosting response of diphtheria and tetanus compared participants with before and after the injection
Description
Boosting response is defined as more 4 times increase of the antibody titer after the injection
Time Frame
28days
Title
solicited adverse events
Time Frame
7days
Title
unsolicited adverse events
Time Frame
28 days
Title
Seroprotection rate according to the respective age group
Time Frame
28days
Title
GMT according to the respective age group
Time Frame
28days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
healthy Korean adults (age: over 18 years)
who got the basic vaccination of DTP(Diphtheria, tetanus, pertussis) in the past
Subjects willing to provide written informed consent and able to comply with the requirements for the study
Exclusion Criteria:
subjects who have already got the additional vaccination of Td within 5 years
subjects with antitoxin of diphtheria and tetanus ≥1.0 IU/mL (ELISA)
only applicable in step I
subjects who have not recovered from the acute disease within 2 weeks
subjects who have the medical history of allergic disease related to the components of investigational drug
who got the treatment of blood product and immunoglobulin product within 3 months
females who are pregnant
females who are breastfeeding
subjects who are infected from the diphtheria and tetanus
subjects who have experienced the severe adverse events for the diphtheria and tetanus vaccination
Subjects who are scheduled to participate in other clinical trial studies during the study
Subjects who have participated in any other clinical trials within 4 weeks of the administration of the study
Those who take the other medicine that affects this study or are vaccinated other vaccines
Subject who have received adrenocortical hormones or immunosuppressive drug within 4weeks of enrollment
Subjects with a history of chronic disease obstacles to the study.
Subjects who have episode of acute febrile (at least 37.4) after injection of vaccine during the study
Subject who have plan of operation during the study.
Individuals with other clinically significant medical or psychological condition who are considered by the investigator to be ineligible for the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
JungHyeon Choi, MD
Organizational Affiliation
Incheon St. Mary's Hospital Catholic University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Incheon St. Mary's Hospital Catholic Univ.
City
Incheon
State/Province
Bupyeong 6-dong, Bupyeong-gu,
ZIP/Postal Code
1544-9004
Country
Korea, Republic of
12. IPD Sharing Statement
Citations:
PubMed Identifier
30686952
Citation
Lee J, Choi JH, Wie SH, Park SH, Choi SM, Lee MS, Kim TH, Lee HJ, Kang JH. A Phase III Study to Evaluate the Immunogenicity and Safety of GC1107 (Adult Tetanus Diphtheria Vaccine) in Healthy Adults. J Korean Med Sci. 2019 Jan 16;34(4):e31. doi: 10.3346/jkms.2019.34.e31. eCollection 2019 Jan 28.
Results Reference
derived
Learn more about this trial
To Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults
We'll reach out to this number within 24 hrs